INC280 showed preliminary anti-tumor efficacy as a single agent in 50% of patients with EGFR wild-type NSCLC with MET dysregulation, as confirmed by FISH (MET/centromere ratio ≥2.0 or MET gene copy number ≥5) or IHC (MET H-score ≥150 or 50% of tumor cells with a staining intensity of 2+ or 3+) [75]. The gene discussed is MET; the disease is non-small cell lung carcinoma.